FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packagehl7.fhir.uv.ebm
Resource TypeEvidenceVariable
IdEvidenceVariable-236950.json
FHIR VersionR6

Resources that use this resource

No resources found


Resources that this resource uses

No resources found


Narrative

Note: links and images are rebased to the (stated) source

Generated Narrative: EvidenceVariable 236950

version: 73; Last updated: 2025-10-07 17:12:54+0000; Language: en

Profile: GroupAssignment

url: https://fevir.net/resources/EvidenceVariable/236950

identifier: FEvIR Object Identifier/236950, FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-group-assignment-85394-85798

name: GroupAssignment_SGLT2_inhibitors_vs_GLP_1_RA

title: GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA

citeAs:

GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236950. Revised 2025-10-07. Available at: https://fevir.net/resources/EvidenceVariable/236950. Computable resource at: https://fevir.net/resources/EvidenceVariable/236950#json.

status: Active

author: Computable Publishing®: MAGIC-to-FEvIR Converter:

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

description:

This EvidenceVariable Resource is referenced in an example for the EBMonFHIR Implementation Guide.

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

RelatesTos

-TypeTarget[x]
*Part OfMAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)

Definitions

-Concept
*Defined in handling and category elements

handling: dichotomous variable

category

name: SGLT2 inhibitors

value: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors

category

name: GLP-1 RA

value: Glucagon-Like Peptide-1 (GLP-1) receptor agonists


Source1

{
  "resourceType": "EvidenceVariable",
  "id": "236950",
  "meta": {
    "versionId": "73",
    "lastUpdated": "2025-10-07T17:12:54.639Z",
    "profile": [
      "http://hl7.org/fhir/uv/ebm/StructureDefinition/group-assignment"
    ]
  },
  "language": "en",
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "url": "https://fevir.net/resources/EvidenceVariable/236950",
  "identifier": [
    {
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code": "ACSN",
            "display": "Accession ID"
          }
        ],
        "text": "FEvIR Object Identifier"
      },
      "system": "https://fevir.net/FOI",
      "value": "236950",
      "assigner": {
        "display": "Computable Publishing LLC"
      }
    },
    {
      "type": {
        "text": "FEvIR Linking Identifier"
      },
      "system": "https://fevir.net/FLI",
      "value": "MAGIC-5288-j1Wqrn-group-assignment-85394-85798",
      "assigner": {
        "display": "Computable Publishing LLC"
      }
    }
  ],
  "name": "GroupAssignment_SGLT2_inhibitors_vs_GLP_1_RA",
  "title": "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA",
  "citeAs": "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236950. Revised 2025-10-07. Available at: https://fevir.net/resources/EvidenceVariable/236950. Computable resource at: https://fevir.net/resources/EvidenceVariable/236950#json.",
  "status": "active",
  "author": [
    {
      "name": "Computable Publishing®: MAGIC-to-FEvIR Converter"
    }
  ],
  "publisher": "Computable Publishing LLC",
  "contact": [
    {
      "telecom": [
        {
          "system": "email",
          "value": "support@computablepublishing.com"
        }
      ]
    }
  ],
  "description": "This EvidenceVariable Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
  "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "relatesTo": [
    {
      "type": "part-of",
      "targetReference": {
        "type": "Composition",
        "identifier": {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "MAGIC-5288-j1Wqrn-conversion-report",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        },
        "display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"
      }
    }
  ],
  "definition": {
    "concept": {
      "coding": [
        {
          "system": "https://fevir.net/resources/CodeSystem/179423",
          "code": "defined-in-handling-and-category",
          "display": "Defined in handling and category elements"
        }
      ]
    }
  },
  "handling": "dichotomous",
  "category": [
    {
      "name": "SGLT2 inhibitors",
      "valueReference": {
        "reference": "Group/236769",
        "type": "Group",
        "identifier": {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "MAGIC-5288-j1Wqrn-intervention-85394-I-85798",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        },
        "display": "Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors"
      }
    },
    {
      "name": "GLP-1 RA",
      "valueReference": {
        "reference": "Group/236776",
        "type": "Group",
        "identifier": {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "MAGIC-5288-j1Wqrn-comparator-85394-C-85798",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        },
        "display": "Glucagon-Like Peptide-1 (GLP-1) receptor agonists"
      }
    }
  ]
}